Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease.

CONCLUSIONS: There is low certainty evidence that CERA has little or no effects on patient-centred outcomes compared with placebo, epoetin alfa or beta or darbepoetin alfa for adults with CKD. The effects of CERA among children who have CKD have not studied in RCTs. PMID: 28782299 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/28782299?dopt=Abstract

Source: Cochrane Database of Systematic Reviews - August 7, 2017 Category: General Medicine Authors: Saglimbene VM, Palmer SC, Ruospo M, Natale P, Craig JC, Strippoli GF Tags: Cochrane Database Syst Rev Source Type: research